Allos Therapeutics Reports 2011 Financial Highlights And Key Business Priorities

Key Business Priorities

• Continue to grow U.S. sales of FOLOTYN for relapsed or refractory PTCL and manage expenses to drive to future profitability
• Pursue regulatory approval to market FOLOTYN for relapsed or refractory PTCL in Europe and the rest of world in collaboration with Mundipharma
• Advance FOLOTYN development program in hematologic malignancies, including first-line PTCL and relapsed or refractory cutaneous T-cell lymphoma in collaboration with Mundipharma
• Explore opportunities to grow product portfolio revenues through product acquisition and/or in-licensing that leverages the Company’s existing infrastructure

Presentation to be Webcast

Members of the Company's senior management will present at the 30th Annual J.P. Morgan Healthcare Conference. The presentation will begin at 10:00 a.m. Pacific Time on Wednesday, January 11, 2012. There will be a live webcast of the presentation, which will be accessible through a link available on the home page and investor relations section of the Allos website. In addition, the webcast will be recorded and available for replay on the Company’s website for 90 days following January 11, 2012.

About Peripheral T-Cell Lymphoma

T-cell lymphomas account for approximately 10% to 15% of all cases of non-Hodgkin lymphomas (NHL). ^1-3 Allos estimates the current annual incidence of PTCL to be approximately 5,900 patients in the U.S. and approximately 6,000 to 7,000 patients in the top five European markets. The outcome of patients with PTCL is poor and the majority of patients ultimately have refractory disease to a variety of agents, including multi-agent chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens. The 5-year overall survival rate in these patients is 25% to 40%, depending on sub-type. ^4-5

About FOLOTYN

FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Sloan-Kettering Institute for Cancer Research, SRI International and Southern Research Institute and developed by Allos Therapeutics. In September 2009, the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated. FOLOTYN has been available to patients in the U.S. since October 2009. An updated analysis of data from PROPEL, the pivotal study of FOLOTYN in patients with relapsed or refractory PTCL, was published in the March 20, 2011 issue of the Journal of Clinical Oncology. FOLOTYN has patent protection through 2017, potentially through July 2022, assuming a five-year patent term extension through the Hatch-Waxman Act.

« First ‹ Previous 1 2 3 4 5 6 Next › Last »